Personalis
PSNL
16.00
-0.03
-0.19%
Personalis
US · PSNL
#2890 by market cap
Listed 2019
16.00
-0.03
-0.19%
Live - 5344 symbols - heartbeat 146s ago
· 2026-10-08 04:13
Pre-market
16.07
+0.46%
After-hours
15.90
-0.63%
- Market cap
- 1.71B
- P/E (TTM)i
- -14.68
- P/Bi
- 7.27
- EPSi
- -0.91
- Div yieldi
- 0.00%
- 52W posi
- 79%
Reader sentiment
Are you bullish or bearish on PSNL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 11.56, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -17.69% YoY
Margins
- Gross margin
- 22.65%
- Operating margin
- -126.43%
- Net margin
- -116.69%
Key ratios & quality
- Altman Z-Scorei
- 11.56
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37.77M | 65.21M | 78.65M | 85.49M | 65.05M | 73.48M | 84.61M | 69.65M |
| Gross profit | 11.81M | 22.08M | 20.11M | 31.66M | 13.35M | 18.21M | 26.83M | 15.78M |
| Selling & admin expenses | 11.27M | 22.08M | 33.69M | 47.70M | 63.97M | 49.73M | 46.19M | 53.57M |
| Research & development | 14.30M | 22.42M | 28.57M | 49.31M | 64.91M | 64.78M | 48.91M | 50.26M |
| Operating profit | -13.77M | -22.42M | -42.15M | -65.35M | -115.53M | -96.29M | -68.27M | -88.06M |
| Pretax profit | -19.88M | -25.08M | -41.22M | -65.21M | -113.28M | -108.21M | -81.27M | -81.25M |
| Tax | 7.00K | 9.00K | 57.00K | 14.00K | 40.00K | 83.00K | 18.00K | 21.00K |
| Net profit | -19.89M | -25.08M | -41.28M | -65.23M | -113.32M | -108.30M | -81.28M | -81.27M |
| Basic EPS | -1 | -1 | -1 | -1 | -2 | -2 | -1 | -1 |
| Diluted EPS | -0.91 | -1.39 | -1.20 | -1.49 | -2.48 | -2.25 | -1.37 | -0.91 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 20.61M | 17.20M | 14.50M | 17.35M | 15.47M | 22.36M |
| Gross profit | 7.21M | 4.76M | 1.91M | 1.90M | 281.00K | 4.74M |
| Selling & admin expenses | 12.26M | 14.18M | 13.03M | 14.09M | 17.90M | 22.00M |
| Research & development | 12.64M | 12.38M | 12.17M | 13.07M | 14.54M | 16.34M |
| Operating profit | -17.70M | -21.80M | -23.29M | -25.27M | -32.16M | -33.59M |
| Pretax profit | -15.74M | -20.05M | -21.65M | -23.80M | -30.02M | -31.68M |
| Tax | 7.00K | 2.00K | 3.00K | 9.00K | 16.00K | 5.00K |
| Net profit | -15.75M | -20.06M | -21.65M | -23.81M | -30.03M | -31.68M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.18 | -0.23 | -0.24 | -0.26 | -0.29 | -0.30 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 29.56M | 139.58M | 220.72M | 318.23M | 199.70M | 146.74M | 203.02M | 267.95M |
| Cash & ST investments | 19.74M | 128.29M | 203.29M | 287.06M | 167.66M | 114.18M | 185.01M | 239.95M |
| Inventory | 2.13M | 1.42M | 2.68M | 4.08M | 6.38M | 5.66M | 3.98M | 5.26M |
| Total assets | 41.67M | 157.29M | 244.84M | 396.53M | 292.70M | 225.10M | 270.27M | 334.16M |
| Total current liabilities | 57.85M | 49.96M | 40.64M | 31.31M | 33.13M | 47.23M | 31.13M | 39.63M |
| Short-term debt | 5.00M | 1.36M | 2.45M | 5.53M | 7.61M | 9.41M | 9.37M | 8.08M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 148,058,000.00 | 50,601,000.00 | 49,897,000.00 | 86,227,000.00 | 74,561,000.00 | 95,658,000.00 | 67,311,000.00 | 72,979,000.00 |
| Total equity | -106.39M | 106.69M | 194.95M | 310.30M | 218.14M | 129.44M | 202.96M | 261.19M |
| Retained earnings | -115.51M | -140.59M | -181.87M | -247.10M | -360.41M | -468.71M | -549.99M | -631.26M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 206.42M | 193.34M | 174.40M | 267.95M | 258.20M | 245.05M |
| Cash & ST investments | 185.69M | 173.23M | 150.52M | 239.95M | 233.22M | 212.66M |
| Inventory | 4.21M | 4.56M | 3.73M | 5.26M | 5.25M | 7.75M |
| Total assets | 273.31M | 258.68M | 242.84M | 334.16M | 325.40M | 312.14M |
| Total current liabilities | 29.89M | 31.72M | 36.16M | 39.63M | 39.05M | 46.39M |
| Short-term debt | 10.31M | 9.05M | 8.37M | 8.08M | 7.76M | 7.83M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 65,963,000.00 | 67,851,000.00 | 71,424,000.00 | 72,979,000.00 | 70,630,000.00 | 76,974,000.00 |
| Total equity | 207.35M | 190.83M | 171.42M | 261.19M | 254.77M | 235.16M |
| Retained earnings | -565.74M | -585.80M | -607.45M | -631.26M | -661.29M | -692.98M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 5.57M | -18.07M | -42.65M | -70.83M | -70.23M | -56.26M | -45.15M | -74.95M |
| Depreciation & amortization | 3.07M | 4.75M | 5.76M | 6.01M | 8.43M | 11.30M | 10.94M | 10.05M |
| Free cash flow | -2.28M | -26.45M | -45.90M | -81.91M | -120.13M | -67.17M | -46.75M | -79.45M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 144.03M | 117.50M | 162.26M | 0 | 3.51M | 97.82M | 126.80M |
| Ending cash balance | 19.74M | 55.05M | 68.53M | 107.38M | 90.92M | 58.77M | 93.21M | 126.04M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -17.96M | -12.94M | -21.80M | -22.25M | -22.48M | -25.77M |
| Depreciation & amortization | 2.59M | 2.53M | 2.47M | 2.46M | 2.37M | 2.41M |
| Free cash flow | -20.47M | -13.23M | -23.43M | -22.32M | -25.67M | -29.55M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 17.78M | 0 | 0 | 109.02M | 20.95M | 4.55M |
| Ending cash balance | 72.79M | 55.16M | 51.76M | 126.04M | 75.38M | 95.76M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -16,611.92 | -27.37 | -25.82 | -42.89 | -62.31 | -48.91 | -35.02 |
| ROA %i | -51.83 | -25.22 | -20.53 | -20.34 | -32.88 | -41.83 | -32.82 | -26.89 |
| ROIC %i | -- | -764.06 | -26.03 | -22.75 | -36.18 | -50.72 | -40.89 | -32.18 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -3,354.06 | -41.46 | -42.99 |
| EBIT margin %i | -47.61 | -36.72 | -52.41 | -76.06 | -173.83 | -147.12 | -96.01 | -116.36 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.51 | 2.79 | 5.43 | 10.16 | 6.03 | 3.11 | 6.52 | 6.76 |
| Quick ratioi | 0.42 | 2.63 | 5.16 | 9.76 | 5.56 | 2.79 | 6.21 | 6.46 |
| Debt / assetsi | 11.99 | 1.27 | 4.49 | 14.71 | 16.62 | 21.20 | 16.37 | 11.95 |
| LT debt / equityi | -- | 0.60 | 4.38 | 17.01 | 18.81 | 29.61 | 17.19 | 12.20 |
| Interest coveragei | -9.50 | -21.13 | -20,610.50 | -353.41 | -562.56 | -982.75 | -3,385.08 | -395.34 |
| Revenue CAGR (3Y) %i | -- | -- | 103.06 | 31.29 | -0.08 | -2.24 | -0.34 | 2.30 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -51.25 | -60.26 | -43.70 | -35.02 | -41.35 | -50.32 |
| ROA %i | -35.88 | -41.12 | -30.61 | -26.89 | -31.92 | -37.55 |
| ROIC %i | -42.27 | -49.16 | -37.30 | -32.18 | -36.60 | -44.03 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -98.03 | -113.58 | -106.69 | -116.36 | -147.71 | -153.49 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.91 | 6.09 | 4.82 | 6.76 | 6.61 | 5.28 |
| Quick ratioi | 6.58 | 5.77 | 4.56 | 6.46 | 6.31 | 4.91 |
| Debt / assetsi | 16.25 | 16.41 | 16.90 | 11.95 | 11.92 | 12.17 |
| LT debt / equityi | 16.45 | 17.50 | 19.05 | 12.20 | 12.18 | 12.83 |
| Interest coveragei | -1,953.60 | -1,112.46 | -530.42 | -395.34 | -425.44 | -502.03 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Provide advanced cancer genomic testing services for precision oncology and personalized testing100.00%
Quote time 2026-10-08 04:13:33 · For reference only, not investment advice and not tailored to your situation.